Successful Treatment of Autoimmune Hemolytic Anemia Concurrent With Gastric Cancer by Rituximab: A Case Report of Evans Syndrome
DOI:
https://doi.org/10.17140/IMOJ-1-101Keywords:
Evans syndrome, Autoimmune hemolytic anemia, Thrombocytopenia, Rituximab, Gastric cancerAbstract
The concurrence of autoimmune hemolytic anemia (AIHA), thrombocytopenic purpura (Evans syndrome) and solid cancer is rare. In this study, we report a diabetic patient with gastric cancer who developed AIHA and idiopathic thrombocytopenic purpura. Steroid therapy for Evans syndrome restored platelet count; however, no improvement in AIHA was observed. Rituximab administration as a second-line therapy resulted in gradual improvement of anemia. Our observation suggested rituximab as an effective therapy for steroid-resistant AIHA.
References
Evans RS, Takahashi K, Duane RT, Payne R, Liu C. Primary thrombocytopenic purpura and acquired hemolytic anemia; evidence for a common etiology. AMA Arch Intern Med. 1951; 87(1): 48-65. doi: 10.1001/archinte.1951.03810010058005
Puthenparambil J, Lechner K, Kornek G. Autoimmune hemolytic anemia as a paraneoplastic phenomenon in solid tumors: A critical analysis of 52 cases reported in the literature. Wien Klin Wochenschr. 2010; 122(7-8): 229-236. doi: 10.1007/ s00508-010-1319-z
Wakata N, Kiyozuka T, Konno S, et al. Autoimmune thrombocytopenic purpura, autoimmune hemolytic anemia and gastric cancer appeared in a patient with myasthenia gravis. Intern Med. 2006; 45(7): 479-481. doi: 10.2169/internal medicine.45.1496
Yonekura S, Nagao T, Arimori S, et al. Evans syndrome associated with gastric plasmacytoma: Case report and a review of the literature. Jpn J Med. 1990; 29(5): 512-515. doi: 10.2169/ internalmedicine1962.29.512
Peñalver FJ, Alvarez-Larrán A, Díez-Martin JL, Gallur L, Jarque I,TsutsumiY. Rituximab is an effective and safe therapeutic alternative in adults with refractory and severe autoimmune hemolytic anemia. Ann Hematol. 2010; 89(11):1073-80.
Barcellini W, Zaja F, Zaninoni A, et al. Low-dose rituximab in adult patients with idiopathic autoimmune hemolytic anemia: clinical efficacy and biologic studies. Blood. 2012; 119(16): 3691-3697. doi: 10.1182/blood-2011-06-363556
Arkenau HT, Müssig O, Buhr T, Jend HH, Porschen R. Microangiopathic hemolytic anemia (MAHA) as paraneoplastic syndrome in metastasized signet ring cell carcinomas: case reports and review of the literature. Z Gastroenterol. 2005; 43(8): 719-722. doi: 10.1055/s-2005-858259
Chung-Delgado K, Revilla-Montag A, Guillen-Bravo S, Rios-Diaz H, Alva-Munoz JC. Refractory thrombocytopenia responds to octreotide treatment in a case of Evans syndrome with gastric neuroendocrine tumor. Case Rep Hematol. 2013; 2013: 391086. doi: 10.1155/2013/391086
D’Arena G, Califano C, Annunziata M, et al. Rituximab for warm-type idiopatic autoimmune hemolytic anemia: A retrospective study of 11 adult patients. Eur J Hematol. 2007; 79(1): 53-58. doi: 10.1111/j.1600-0609.2007.00861.x
Barcellini W, Zaja F, Zaninoni A, et al. Sustained response to low-dose rituximab in ideopathic autoimmune hemolytic anemia. Eur J Hematol. 2013; 91(6): 546-551. doi: 10.1111/ ejh.12199
Maung SW, Leahy M, O’Leary HM, et al. A multi-centre retrospective study of rituximab use in the treatment of relapsed or resistant warm autoimmune haemolytic anaemai. Brit J Haemot. 2013; 163(1): 118-122. doi: 10.1111/bjh.12486
Published
How to Cite
Issue
Section
License
This work is licensed under a Creative Commons Attribution 4.0 International License.
All content published in Internal Medicine (IMOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.